Ribonucleic acid, or RNA, has emerged as a hot new field after mRNA and miRNA discoveries won Nobel Prizes in 2023 and 2024, respectively, drawing attention to its scientific value and industrial potential. In the medical field, RNA-based small nucleic acid drugs, by virtue of their broad target selection scope, higher clinical success rates, and durable effects, are poised to become leaders driving a third wave of highly targeted new drugs, following small-molecule drugs and antibody therapeutics. Against that backdrop, international investors will soon have a chance to buy into China's leading company within the small nucleic acid drugs sector.
近年，RNA（核糖核酸）领域在连续获得诺贝尔奖认可，mRNA和miRNA的相关发现分别在2023年、2024年获奖，其科学价值与产业潜力备受关注。以RNA为基础的小核酸药物凭借其靶点选择范围广、临床开发成功率相对较高、作用持久等优势，有望成为继小分子药物、抗体药物之后，现代新药第三次浪潮的引领者。如今，国际投资者即将可以参与投资manbetx3.0 小核酸药物领域的领军企业。